Saturday 17 October 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.01
−4.55%
Follow ENLV
| Older periods | Jun '25 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.41 | 6.43 | 193.24 | 119.39 |
Net Debt/EBITDA |
6.52 | 7.35 | 300.51 | 881.46 | |
Debt/Assets |
0.00% | 0.00% | 0.02% | 0.35% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.89 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.08) | (0.26) | (0.11) | — | |
Interest Coverage |
2.54 | — | — | (3.12) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(0.76) | (1.24) | (0.86) | 0.00 | |
Cash per Share |
12.27 | 11.35 | 570.50 | 226.56 | |
Shareholders Equity per Share |
11.98 | 10.90 | 634.85 | 235.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.98 | 10.90 | 634.85 | 235.67 | |
Free Cash Flow |
(1.20) | (1.99) | (2.63) | — | |
Working Capital |
18.00 | 16.47 | 1,734.16 | 3,719.58 | |
Capital Expenditures |
(0.01) | (0.02) | (0.01) | — | |
Net Current Asset Value |
17.78 | 16.04 | 1,351.13 | 2,749.28 | |
| Other line items | |||||
Quick Ratio |
5.86 | 6.01 | 192.75 | 119.28 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.75) | (1.23) | (0.86) | 0.00 | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Average Payables |
0.42 | 0.23 | 2.31 | 1.11 | |
Average Assets |
27.25 | 25.37 | 1,177.34 | 2,462.00 | |
Average Common Equity |
23.81 | 22.03 | 979.27 | 1,959.43 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026